This report was first published by Endpoints News. To see the original version, click here
CirCode Biomed, a Chinese startup working on an experimental class of genetic medicines known as circular RNA, has received the FDA’s blessing to begin a clinical trial in the US, the company told Endpoints News in an exclusive interview.
The Shanghai-based startup appears to be only the second drugmaker with FDA clearance to test a circular RNA therapy. The first was RiboX Therapeutics, also based in Shanghai, which began its own US trial last spring, Endpoints previously reported. Three well-funded Boston startups focused on circular RNA — two of which were recently acquired by Bristol Myers Squibb and Eli Lilly — have yet to start clinical trials.
您已阅读17%（747字），剩余83%（3608字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。